The innovative technology behind
protexam– clinical proteome analysis – makes the test unique.
Protexam's clinical proteomic analysis was developed over 20 years of clinical research.
The basis of the protexam-Diagnostics is based on two decades of intensive research with international scientists. During this time, the technology was developed, the database was built and disease-specific protein patterns were defined. Clinical proteome analysis is carried out by coupling capillary electrophoresis and mass spectrometry (CE-MS). It is always used in clinical studies. We will continue to generate disease-specific protein patterns in the future.
85,000
_____________________________
Samples and data sets
400
_____________________________
Scientific publications
100
_____________________________
clinical studies
With the
Prof. Dr. Dr. Harald Mischak developed and patented CE-MS technology allows diseases to be diagnosed early and precisely. By comparing the proteome with the previously defined disease-specific protein patterns in the database, the individual health status can be mapped.
The advantage for you is that the disease is detected at a time when suitable therapy can still prevent damage to the organs. The medicine of the future will be increasingly individualized, and will be more strongly influenced by the idea of optimizing one's own body than by repairing temporary deficits.
Research into disease markers usually begins with an initial request from scientists at university hospitals. With each clinical study, new findings from proteomic analysis are added to create and validate new disease profiles. All data from the studies are fed into our database. Further studies are planned for your benefit in the future.
Our strength is that we can compare every sample with the many data sets in our database. Every disease has its own disease-specific protein pattern. Every sample contains thousands of proteins and their fragments (peptides). We analyze these qualitatively and quantitatively with your sample. The high precision of
protexam
is not based on a single but on a combination of hundreds of disease markers.
Some of the prominent scientists involved in the clinical trials on the basis of protexam were involved:
Prof. Dr.
Antonia Vlahou
